



Date:

Jan-17

2025

Contact Information

For questions or additional assistance, contact:

Provider Relations 956-632-8308

To enter authorization requests and upload clinical via the Provider Portal, visit driscollhealthplan.com/providers

To verify authorization requirements via the Authorization Requirement Portal, visit driscollhealthplan.com/priorauthcheck

To submit authorization requests or clinical to the UM Dept. via fax, send to 1-866-741-5650

Attention: Authorization Requirement Updates

Effective 02/01/2025, DHP <u>will</u> require prior authorization for the following procedure codes:

Pharmacy Services

- J0870, Rytelo (imetelstat) is an oligonucleotide telomerase inhibitor indicated for the treatment of members 18 years or older with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring four or more red blood cell (RBC) units over eight weeks who have not responded to, have lost response to, or are ineligible for erythropoiesis-stimulating agents (ESA)
- J0175, donanemab-azbt (Kisunla) is an amyloid-beta directed antibody indicated to treat Alzheimer's disease by reducing amyloid-beta plaques in clients with mild cognitive impairment or mild dementia stage of disease

Sleep Study Services

 95800, a new home sleep study test for members 18 years of age and older, a device that measures 3 or more channels, including pulse oximetry, actigraphy, and peripheral arterial tone (PAT), limited to 1 study per day and 2 per rolling year

Please note: Procedure code J0172, aducanumab-avwa (Aduhelm) will be removed from the TMPPM Outpatient Drugs Services Handbook effective 02/01/2025. The manufacturer discontinued the medication effective November 2024.

* To access the DHP provider portal, visit driscollhealthplan.com